Journal of Medicinal Chemistry · 2005 · 42 citations · 15 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryPharmacophore ModelingEnzyme InhibitionHit-to-lead OptimizationLead Compound DesignLead DiscoveryPharmacophore-based Lead DiscoveryStructure-based Pharmacophore ModelingActivator Protein 1 ActivationLead HoppingPharmacophore Model ConstructionPharmacophore Model RefinementSignal TransactivationStructure-based Lead DiscoveryStructure-based Pharmacophore DesignStructure-guided Lead Discovery
We designed and synthesized small-molecule activator protein-1 (AP-1) inhibitors based on a three-dimensional (3D) pharmacophore model that we had previously derived from a cyclic decapeptide exhibiting AP-1 inhibitory activity. New AP-1 inhibitors with a 1-thia-4-azaspiro[4.5]decane or a benzophenone scaffold, which inhibit the DNA-binding and transactivation activities of AP-1, were discovered using a "lead hopping" procedure. An additional investigation of the benzophenone analogues confirmed the reliability of the pharmacophore model, its utility to discover AP-1 inhibitors, and the potency of the benzophenone derivatives as a lead series.
15
New coupling reagents in peptide chemistry
Reinhard Knorr, Arnold Trzeciak, Willi Bannwarth et al. · Tetrahedron Letters · 1989 · 986 citations
Alexander R. Mitchell, B W Erickson, M. N. Ryabtsev et al. · Journal of the American Chemical Society · 1976 · 252 citations